Dosage form, especially for muscular balance
DE202025102658U1Undetermined Publication Date: 2026-08-13MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEB GESELLSCHAFT MBH
4 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- DE · DE
- Patent Type
- Utility models
- Current Assignee / Owner
- MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEB GESELLSCHAFT MBH
- Filing Date
- 2025-05-14
- Publication Date
- 2026-08-13
Abstract
Dosage form, in particular a dietary supplement dosage form (food supplement) or pharmaceutical dosage form, preferably a dietary supplement dosage form (food supplement), in particular for oral administration, preferably a dosage form for use in the maintenance and / or restoration, preferably regulation and / or normalization, of muscle health and / or muscle physiology, wherein the dosage form is designed as a multiphase, in particular at least two-phase, preferably two-phase, dosage form, in particular a tablet, wherein the multiphase, in particular at least two-phase, preferably two-phase, dosage form comprises at least two, preferably (exactly) two, distinct phases, in particular at least two, preferably (exactly) two, distinct layers.with or consisting of different disintegration times and / or release rates when administered orally, wherein a first phase, in particular a first layer, is formed with rapid and / or immediate disintegration and / or release, wherein the first phase, in particular the first layer, comprises at least one cinchona bark extract, in particular dry cinchona bark extract, preferably dry bark extract (Extractum e cortex siccum) of at least one Cinchona species, particularly preferably dry bark extract (Extractum e cortex siccum) of Cinchona pubescens, wherein a second phase, in particular a second layer, is formed with slow and / or delayed (controlled) disintegration and / or release, wherein the first phase and / or the second phase, in particular at least the second phase, preferably the first phase and the second phase,comprising at least one physiologically compatible magnesium compound, in particular a magnesium salt; in particular wherein the first phase and / or the second phase, in particular at least the second phase, preferably the first phase and the second phase, comprises at least one further ingredient selected from the group of B vitamins, D vitamins and K vitamins, as well as combinations or mixtures thereof.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Use of adenosine receptor agonists in therapy
EP1603576A1
Oil separator for vapor compression system compressor
EP1782002A1
Use of adenosine receptor agonists in therapy
US20060234975A1
Use of adenosine receptor agonists in therapy
WO2004078184A1